HHS Secretary Azar avoids being drawn into fight over preexisting conditions

The HHS secretary contends drug manufacturers face hurdles in trying to lower prescription prices.


Health and Human Services Secretary Alex Azar told lawmakers Tuesday that he wants to preserve access to affordable insurance for Americans with preexisting medical conditions, but he declined to disclose his view of an administration move that could undercut such consumer protections. 

Calling it "a constitutional position . . . not a policy position," Azar sidestepped grilling on whether he agreed with a legal brief filed last week by Justice Department attorneys stating they would not defend the Affordable Care Act in a federal lawsuit by Texas and 19 other Republican-led states. 

During a hearing before the Senate Health, Education, Labor and Pensions Committee that was mainly about the president's blueprint to address drug prices, Sen. Maggie Hassan, D-N.H., told Azar that Justice's legal position is "like some kind of a sick joke." The administration argues that the ACA's individual mandate, requiring most people to carry health insurance, will become unconstitutional next year — and, with it, the law's insurance protections for consumers. 

"Will you encourage the Trump administration to change its position?" Hassan challenged Azar, a lawyer and former HHS general counsel. 

He replied that "we do believe in finding solutions on the matter of preexisting conditions and the matter of affordability, regardless of the litigation." 

The committee's Republicans were silent on the question, even though some GOP lawmakers have said they were bewildered by the Justice Department's surprise stance. The move has become a lightning rod ahead of the November midterm elections. 

Democrats also pressed Azar on a statement by President Donald Trump last month that drug companies would, within two weeks, "announce voluntary, massive drops in prices." 

"That would be tomorrow," noted Sen. Elizabeth Warren, D-Mass., challenging Azar to name companies that have carried out Trump's promise. 

The secretary said several drug manufacturers have told federal officials that "they want to execute substantial price reductions" but are "encountering hurdles." Pharmacy benefit managers (PBMs), he said, are threatening to drop those companies' drugs from formularies — that is, lists of medicines covered by an insurer — because lower list prices would translate into smaller profits for the PBMs. "I find that unconscionable," he said. 

Azar's remarks were consistent with the administration's portrayal of "middle men," not the pharmaceutical industry itself, as the root of the nation's high drug prices. He reiterated that direct government negotiation of drug prices in the vast Medicare program — a longtime Democratic goal that Trump embraced during his campaign — would be ineffective. 

Azar noted that the Food and Drug Administration on Tuesday issued final guidelines designed to make it easier for pharmaceutical companies and insurers to negotiate prices based on a drug's value and effectiveness. 

The rules, first drafted during the final days of the Obama administration, define permissible "medical communications" between the manufacturers and payers such as health plans and hospitals. They fit within a priority of Azar's to shift health-care payments from methods based on the amount of treatment provided to ones based on services' quality and effectiveness. 

FDA Commissioner Scott Gottlieb said the guidance clarifies how drug companies may communicate information about patient outcomes that are important to purchasers, but are not expressly included in a product's approved labeling. 

For example, Gottlieb said in an interview, drug companies might have information on how a particular drug helps to reduce the length of hospital stays or whether patients need to be readmitted to a hospital. While such data are not part of the approved labels, they "may be of interest to health plans and easy to measure." 

His agency wants to encourage competitive contracting based on such measures and "not get in the way" of such negotiations, he added. 

Drug companies develop information on the economic value of their medications. But they have indicated to the FDA that they feel inhibited in sharing certain economic data with payers because of legal concerns. 

A spokesman for the Pharmaceutical Research and Manufacturers of America, the main trade group for the drug industry, praised the new guidelines. They address "one barrier that has restricted how much information biopharmaceutical companies can share with insurance companies about the potential value of a medicine," the spokesman said.


Reader Comments ...


Next Up in Nation & World

The New York Times joins effort to combat Trump’s anti-press rhetoric
The New York Times joins effort to combat Trump’s anti-press rhetoric

 The call to arms came in the form of a memo.  Marjorie Pritchard, the deputy managing editor of The Boston Globe, reached out to editorial boards at other newspapers last week.  “We propose to publish an editorial on August 16 on the dangers of the administration’s assault on the press and ask others to commit to publishing...
Twitter suspends Infowars founder’s account over a Tweet
Twitter suspends Infowars founder’s account over a Tweet

Twitter on Tuesday suspended the account of far-right conspiracy theorist Alex Jones for a week after he tweeted a link to a video calling for supporters to get their “battle rifles” ready against media and others, in a violation of the company’s rules against inciting violence.  The action effectively prevents Jones from tweeting...
White House press secretary can’t guarantee public won’t hear Trump use N-word on audio recording
White House press secretary can’t guarantee public won’t hear Trump use N-word on audio recording

White House press secretary Sarah Huckabee Sanders said Tuesday that she couldn't guarantee that the American people will never hear President Donald Trump uttering the n-word on an audio recording, as a former senior White House adviser continued a publicity tour to promote her new book depicting the president as a racist.  The briefing by Sanders...
‘He created Omarosa’: How Trump’s protegee turned his tactics against him
‘He created Omarosa’: How Trump’s protegee turned his tactics against him

Omarosa Manigault Newman's new book comes with an explosive title. ("Unhinged.") It has a healthy frisson of tension followed by a climactic reveal. (She taped her colleagues! In the White House Situation Room!) And it has just enough cliffhangers to keep viewers coming back for more. (She may or may not have heard a recording of President...
Parliament car crash: Salih Khater named as suspect in possible terror attack, reports say
Parliament car crash: Salih Khater named as suspect in possible terror attack, reports say

A man arrested on suspicion of terrorist offenses in connection with a Tuesday morning car crash outside the Houses of Parliament in London has been identified as Salih Khater, British media outlets are reporting. Update 5:45 a.m. EDT Aug. 15: More details are emerging about the man accused of driving a car through security barriers and injuring pedestrians...
More Stories